ITGA2B and acute coronary syndrome: It is our opinion that actual data, as reviewed here, may sustain a more extensive use of GP IIb/IIIa inhibitors in patients presenting with acute coronary syndromes, strictly based on the definition for a high risk procedure: complexity, angiographic characteristics and patient’s risk profile, regardless whether STEMI or NSTEMI.